Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTINOSE FLUTICASONE vs Flovent HFA in Mild to Moderate Asthma
NCT02266927Phase 1Completed
- Sponsor
- OptiNose
- Start
- Sep 2014
- Primary completion
- Mar 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fluticasone in asthma (2 arms), sponsored by OptiNose. Primary endpoint: Area Under the Curve from time zero to infinity at 36 hours. Started Sep 2014; status: completed.
02
Drugs
fluticasone
03
Conditions
asthma
Beyond the preview
Go deeper on NCT02266927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02266927.